{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:49:41Z","timestamp":1790254181240,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T00:00:00Z","timestamp":1529452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00280-018-3623-7","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T02:35:44Z","timestamp":1529462144000},"page":"407-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer"],"prefix":"10.1007","volume":"82","author":[{"given":"Amita","family":"Patnaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0667-2620","authenticated-orcid":false,"given":"Kyri","family":"Papadopoulous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Rasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Muralidhar","family":"Beeram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8123-4065","authenticated-orcid":false,"given":"Filip","family":"Janku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Hynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6545-7763","authenticated-orcid":false,"given":"Sushma R.","family":"Gundala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda D.","family":"Willard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee Bence","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-1609","authenticated-orcid":false,"given":"David","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,20]]},"reference":[{"key":"3623_CR1","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-16-0951","volume":"22","author":"S Hartmann","year":"2016","unstructured":"Hartmann S, Bhola NE, Grandis JR (2016) HGF\/Met signaling in head and neck cancer: impact on the tumor microenvironment. Clin Cancer Res 22:4005\u20134013","journal-title":"Clin Cancer Res"},{"key":"3623_CR2","doi-asserted-by":"publisher","first-page":"e84700","DOI":"10.1371\/journal.pone.0084700","volume":"8","author":"S Nanjo","year":"2013","unstructured":"Nanjo S, Yamada T, Nishihara H, Takeuchi S, Sano T, Nakagawa T, Ishikawa D, Zhao L, Ebi H, Yasumoto K, Matsumoto K, Yano S (2013) Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. PLoS One 8:e84700","journal-title":"PLoS One"},{"key":"3623_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/1547691X.2016.1251512","volume":"14","author":"ES Qamsari","year":"2017","unstructured":"Qamsari ES, Sharifzadeh Z, Bagheri S, Riazi-Rad F, Younesi V, Abolhassani M, Ghaderi SS, Baradaran B, Somi MH, Yousefi M (2017) Isolation and characterization of anti c-met single chain fragment variable (scFv) antibodies. J Immunotoxicol 14:23\u201330","journal-title":"J Immunotoxicol"},{"key":"3623_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14728222.2011.648617","volume":"16","author":"P Seshacharyulu","year":"2012","unstructured":"Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16:15\u201331","journal-title":"Expert Opin Ther Targets"},{"key":"3623_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc3205","volume":"12","author":"E Gherardi","year":"2012","unstructured":"Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89\u2013103","journal-title":"Nat Rev Cancer"},{"key":"3623_CR6","doi-asserted-by":"publisher","first-page":"a009209","DOI":"10.1101\/cshperspect.a009209","volume":"5","author":"CR Graveel","year":"2013","unstructured":"Graveel CR, Tolbert D, Vande Woude GF (2013) MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol 5:a009209","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3623_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ctrv.2013.06.002","volume":"40","author":"J Remon","year":"2014","unstructured":"Remon J, Mor\u00e1n T, Majem M, Reguart N, Dalmau E, M\u00e1rquez-Medina D, Lianes P (2014) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. Cancer Treat Rev 40:93\u2013101","journal-title":"Cancer Treat Rev"},{"key":"3623_CR8","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/nm.3388","volume":"19","author":"CR Chong","year":"2013","unstructured":"Chong CR, Janne PA (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19:1389\u20131400","journal-title":"Nat Med"},{"key":"3623_CR9","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/0008-5472.CAN-09-3620","volume":"70","author":"U McDermott","year":"2010","unstructured":"McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J (2010) Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 70:1625\u20131634","journal-title":"Cancer Res"},{"key":"3623_CR10","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, J\u00e4nne PA (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039\u20131043","journal-title":"Science"},{"key":"3623_CR11","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1097\/JTO.0b013e31823ab0dd","volume":"6","author":"S Yano","year":"2011","unstructured":"Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M (2011) Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 6:2011\u20132017","journal-title":"J Thorac Oncol"},{"issue":"Suppl 1","key":"3623_CR12","first-page":"13","volume":"7","author":"I Garajov\u00e1","year":"2015","unstructured":"Garajov\u00e1 I, Giovannetti E, Biasco G, Peters GJ (2015) c-Met as a target for personalized therapy. Transl Oncogenom 7(Suppl 1):13\u201331","journal-title":"Transl Oncogenom"},{"key":"3623_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ijc.30049","volume":"139","author":"C Eng","year":"2016","unstructured":"Eng C, Bessudo A, Hart LL, Severtsev A, Gladkov O, Muller L, Kopp ML, Vladimirov V, Langdon R, Kotiv B, Barni S, Hsu C, Bolotin E, von Roemeling R, Schwartz B, Bendell JC (2016) A randomized, placebo-controlled, phase 1\/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. Int J Cancer 139:177\u2013186","journal-title":"Int J Cancer"},{"key":"3623_CR14","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1158\/1078-0432.CCR-16-1418","volume":"23","author":"LS Rosen","year":"2017","unstructured":"Rosen LS, Goldman JW, Algazi AP, Turner PK, Moser B, Hu T, Wang XA, Tuttle J, Wacheck V, Wooldridge JE, Banck M (2017) A first-in-human phase I study of a bivalent MET antibody, emibetuzumab (LY2875358), as monotherapy and in combination with erlotinib in advanced cancer. Clin Cancer Res 23:1910\u20131919","journal-title":"Clin Cancer Res"},{"key":"3623_CR15","doi-asserted-by":"publisher","first-page":"11337","DOI":"10.1074\/jbc.M116.714287","volume":"291","author":"JJ Rhoden","year":"2016","unstructured":"Rhoden JJ, Dyas GL, Wroblewski VJ (2016) A modeling and experimental investigation of the effects of antigen density, binding affinity, and antigen expression ratio on bispecific antibody binding to cell surface targets. J Biol Chem 291:11337\u201311347","journal-title":"J Biol Chem"},{"key":"3623_CR16","unstructured":"Eli Lilly and Company (2016) Erbitux\u00ae (cetuximab). Highlights of prescribing information. \n                    http:\/\/pi.lilly.com\/us\/erbitux-uspi.pdf\n                    \n                  . Accessed 16 Mar 2018"},{"issue":"14 Suppl","key":"3623_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1158\/1538-7445.AM2016-873","volume":"76","author":"L Liu","year":"2016","unstructured":"Liu L, Zeng W, Chedid M, Zeng Y, Tschang S, Tian Tang Y, Lu JY (2016) A novel MET-EGFR bispecific antibody LY3164530 shows advantage over combining MET and EGFR antibodies in tumor inhibition and overcome resistance. AACR; Cancer Res 76(14 Suppl):873","journal-title":"AACR; Cancer Res"},{"key":"3623_CR18","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1200\/JCO.2012.45.7903","volume":"31","author":"Y Ji","year":"2013","unstructured":"Ji Y, Wang SJ (2013) Modified toxicity probability interval design: a safer and more reliable method than the 3\u2009+\u20093 design for practical phase I trials. J Clin Oncol 31:1785\u20131791","journal-title":"J Clin Oncol"},{"key":"3623_CR19","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/bimj.201600084","volume":"59","author":"M Ursino","year":"2017","unstructured":"Ursino M, Zohar S, Lentz F, Alberti C, Friede T, Stallard N, Comets E (2017) Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations. Biom J 59:804\u2013825","journal-title":"Biom J"},{"key":"3623_CR20","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","volume":"76","author":"SL Moores","year":"2016","unstructured":"Moores SL, Chiu ML, Bushey BS, Chevalier K, Luistro L, Dorn K, Brezski RJ, Haytko P, Kelly T, Wu SJ, Martin PL, Neijssen J, Parren PW, Schuurman J, Attar RM, Laquerre S, Lorenzi MV II, Anderson GM (2016) A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res 76:3942\u20133953","journal-title":"Cancer Res"},{"key":"3623_CR21","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1038\/onc.2015.514","volume":"35","author":"JM Lee","year":"2016","unstructured":"Lee JM, Lee SH, Hwang JW, Oh SJ, Kim B, Jung S, Shim SH, Lin PW, Lee SB, Cho MY, Koh YJ, Kim SY, Ahn S, Lee J, Kim KM, Cheong KH, Choi J, Kim KA (2016) Novel strategy for a bispecific antibody: induction of dual target internalization and degradation. Oncogene 35:4437\u20134446","journal-title":"Oncogene"},{"key":"3623_CR22","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1038\/onc.2013.245","volume":"32","author":"R Castoldi","year":"2013","unstructured":"Castoldi R, Ecker V, Wiehle L, Majety M, Busl-Schuller R, Asmussen M, Nopora A, Jucknischke U, Osl F, Kobold S, Scheuer W, Venturi M, Klein C, Niederfellner G, Sustmann C (2013) A novel bispecific EGFR\/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. Oncogene 32:5593\u20135601","journal-title":"Oncogene"}],"updated-by":[{"DOI":"10.1007\/s00280-018-3641-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000}}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3623-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3623-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3623-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T19:06:21Z","timestamp":1560971181000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3623-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,20]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["3623"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3623-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00280-018-3641-5","asserted-by":"object"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,20]]},"assertion":[{"value":"22 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article unfortunately contained a mistake. The co-authors\u2019 names were incorrect.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AP has received institutional research funding from Eli Lilly. MG reports a pending patent on clinical trial decision-making. DR has served on a scientific advisory board for Eli Lilly. SF has received clinical study support from Aneropharma Science, Inc, Aprea AB, AstraZeneca, Eli Lilly, Endocyte, Ignyta, Millennium, NCCI, Novartis, OncoMed Pharmaceuticals, Inc, Vertex Pharmaceuticals, Inc, and Hengrui. FJ has received grant funding from Symphogen and Deciphera. SH, SRG, MDW, WZ, and ABL are employees and stockholders of Eli Lilly. ABL\u2019s spouse is also an employee and stockholder of Eli Lilly. DH has received grant funding from Bayer, Eli Lilly, Genentech, LOXO, Pfizer, Amgen, Mirati, Ignyta, Merck, Daichii-Sanko, Eisai, and Mirno; travel fees from Mirna and LOXO; served as a consultant\/advisor for Bayer, Baxter, and Guidepoint Global; and is the owner and founder of Oncoresponse. All other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}